Evidence map›Paper›PMID 34884526›Full record

ArticleInternational journal of molecular sciences2021

3D Printed Cobalt-Chromium-Molybdenum Porous Superalloy with Superior Antiviral Activity.

Arun Arjunan, John Robinson, Ahmad Baroutaji, Alberto Tuñón-Molina, Miguel Martí, Ángel Serrano-Aroca

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Nano-Based 3D Printed Scaffold for Bone Tissue Engineering.Bioengineering (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Frontiers in Antimicrobial Materials.International journal of molecular sciences · 2022
    Article
  6. Review
  7. Alginate: Enhancement Strategies for Advanced Applications.International journal of molecular sciences · 2022
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arun ArjunanCentre for Engineering Innovation and Research, Additive Manufacturing of Functional Materials (AMFM) Research Group, Faculty of Science and Engineering, Telford Innovation Campus, University of Wolverhampton, Telford TF2 9NT, UK.ORCID 0000-0001-5493-0957
John RobinsonCentre for Engineering Innovation and Research, Additive Manufacturing of Functional Materials (AMFM) Research Group, Faculty of Science and Engineering, Telford Innovation Campus, University of Wolverhampton, Telford TF2 9NT, UK.ORCID 0000-0001-6858-2367
Ahmad BaroutajiCentre for Engineering Innovation and Research, Additive Manufacturing of Functional Materials (AMFM) Research Group, Faculty of Science and Engineering, Telford Innovation Campus, University of Wolverhampton, Telford TF2 9NT, UK.
Alberto Tuñón-MolinaBiomaterials and Bioengineering Lab, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, 46001 Valencia, Spain.ORCID 0000-0003-3819-7390
Miguel MartíBiomaterials and Bioengineering Lab, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, 46001 Valencia, Spain.ORCID 0000-0002-1891-8368
Ángel Serrano-ArocaBiomaterials and Bioengineering Lab, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, 46001 Valencia, Spain.ORCID 0000-0002-9953-3848

Funding

European Commission 32R19P03053Fundación Universidad Católica de Valencia San Vicente Mártir 2020-231-006UCVSpanish Ministry of Science and Innovation PID2020-119333RB-I00 / AEI / 10.13039/501100011033
6 · The paper itself

Abstract

COVID-19 pandemic and associated supply-chain disruptions emphasise the requirement for antimicrobial materials for on-demand manufacturing. Besides aerosol transmission, SARS-CoV-2 is also propagated through contact with virus-contaminated surfaces. As such, the development of effective biofunctional materials that can inactivate SARS-CoV-2 is critical for pandemic preparedness. Such materials will enable the rational development of antiviral devices with prolonged serviceability, reducing the environmental burden of disposable alternatives. This research reveals the novel use of Laser Powder Bed Fusion (LPBF) to 3D print porous Cobalt-Chromium-Molybdenum (Co-Cr-Mo) superalloy with potent antiviral activity (100% viral inactivation in 30 min). The porous material was rationally conceived using a multi-objective surrogate model featuring track thickness (tt) and pore diameter (ϕd) as responses. The regression analysis found the most significant parameters for Co-Cr-Mo track formation to be the interaction effects of scanning rate (Vs) and laser power (Pl) in the order PlVs>Vs>Pl. Contrastively, the pore diameter was found to be primarily driven by the hatch spacing (Sh). The study is the first to demonstrate the superior antiviral properties of 3D printed Co-Cr-Mo superalloy against an enveloped virus used as biosafe viral model of SARS-CoV-2. The material significantly outperforms the viral inactivation time of other broadly used antiviral metals such as copper and silver, as the material's viral inactivation time was from 5 h to 30 min. As such, the study goes beyond the current state-of-the-art in antiviral alloys to provide extra protection to combat the SARS-CoV-2 viral spread. The evolving nature of the COVID-19 pandemic brings new and unpredictable challenges where on-demand 3D printing of antiviral materials can achieve rapid solutions while reducing the environmental impact of disposable devices.

Indexed as

Printing, Three-DimensionalAlloysAntiviral AgentsChromiumCobaltCOVID-19HumansMolybdenumPorositySARS-CoV-2Surface PropertiesVirus InactivationAlloysAntiviral AgentsChromiumCobaltMolybdenum3D printingantiviralChromiumCobaltCOVID-19Laser Powder Bed FusionMolybdenumSARS-CoV-2superalloy

Identifiers

PMID34884526
PMCPMC8657688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.